Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Georgia: - Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
- Northside Hospital — Atlanta, Georgia
- John B Amos Cancer Center — Columbus, Georgia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Georgia: - Augusta University Medical Center — Augusta, Georgia
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Georgia: - Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Georgia: - Piedmont Hospital — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Georgia: - Children's Healthcare of Atlanta — Atlanta, Georgia
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Georgia: - Emory University — Atlanta, Georgia
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Georgia: - Piedmont Atlanta Hospital — Atlanta, Georgia
- Winship Cancer Institute of Emory University — Atlanta, Georgia
Phase 3 Recruiting Industry
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…
Sponsor: CarThera
NCT ID: NCT05902169
Sites in Georgia: - Winship Cancer Institute at Emory University — Atlanta, Georgia
Phase 3 Recruiting Industry
This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Sites in Georgia: - Emory Winship Cancer Institute — Atlanta, Georgia
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Georgia: - Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Georgia: - Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Georgia: - Children's Healthcare of Atlanta - Egleston Hospital — Atlanta, Georgia
Phase 2 Recruiting Network
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual app…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06319027
Sites in Georgia: - Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Phase 2 Recruiting Industry
This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with l…
Sponsor: BrainChild Bio, Inc
NCT ID: NCT07680439
Sites in Georgia: - Children's Healthcare of Atlanta — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Academic/Other
This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent). Visudyne is FDA ap…
Sponsor: Emory University
NCT ID: NCT04590664
Sites in Georgia: - Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Georgia: - Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Phase 1 Recruiting Academic/Other
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary…
Sponsor: Sabine Mueller, MD, PhD
NCT ID: NCT04732065
Sites in Georgia: - Emory University — Atlanta, Georgia
Phase 1 Recruiting Academic/Other
Recent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tumor-associated antigen-presenting cells. The central clinical hypothesis for the…
Sponsor: Theodore S. Johnson
NCT ID: NCT05106296
Sites in Georgia: - Augusta University, Georgia Cancer Center — Augusta, Georgia
EARLY Phase 1 Recruiting Academic/Other
This early phase I trial evaluates different administration techniques (oral or intravenous) for arginine and tests the safety of giving arginine with whole brain radiation therapy in patients who have cancer that has spread from where it …
Sponsor: Emory University
NCT ID: NCT06328686
Sites in Georgia: - Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Recruiting Industry
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT04427384
Sites in Georgia: - Piedmont Healthcare — Atlanta, Georgia
- Winship Cancer Institute of Emory University — Atlanta, Georgia
NA Recruiting Academic/Other
This trial studies how well spectroscopic magnetic resonance imaging (MRI) guided proton therapy works in assessing metabolic change in pediatric patients with brain tumors. The non-invasive imaging, such as spectroscopic MRI may help to m…
Sponsor: Emory University
NCT ID: NCT04908709
Sites in Georgia: - Emory Proton Therapy Center — Atlanta, Georgia
- Children's Healthcare of Atlanta - Scottish Rite — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
NA Recruiting Academic/Other
This clinical trial tests the safety and side effects of tumor treating fields in treating patients with gliomas located in the brainstem. Optune is a wearable, portable, treatment that creates low-intensity, wave-like electric fields call…
Sponsor: Emory University
NCT ID: NCT05310448
Sites in Georgia: - Emory Proton Therapy Center — Atlanta, Georgia
- Emory University/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
NA Recruiting Academic/Other
This clinical trial evaluates the impact of a research intervention of virtually supervised exercise program (RISE) on cancer-related cognitive impairment (CRCI), physical activity in adolescent and young adult (AYA) brain tumor survivors.…
Sponsor: Emory University
NCT ID: NCT06799481
Sites in Georgia: - Emory University Hospital — Atlanta, Georgia
NA Recruiting Academic/Other
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of t…
Sponsor: Emory University
NCT ID: NCT04278118
Sites in Georgia: - Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia